NEWRON PHARMACEUT. EO-20 (NP5) — Cash Flow Quality Index

Latest as of December 2024: -0.34x

NEWRON PHARMACEUT. EO-20 (NP5) has a Cash Flow Quality Index of -0.34x as of December 2024. Operating cash flow of €-8.65 Million is below net income of €25.50 Million, suggesting accrual-heavy earnings not yet converted to cash. Also explore NEWRON PHARMACEUT. EO-20 balance sheet assets for the complete picture of this company's asset base.

Cash Flow Quality Index

-0.34x
Operating CF / Net Income

Operating Cash Flow

€-8.65 Million
EUR

Net Income

€25.50 Million
EUR

Data as of

Dec 2024
Most recent filing

NEWRON PHARMACEUT. EO-20 Cash Flow Quality Index (2024–2024)

Historical Cash Flow Quality Index for NEWRON PHARMACEUT. EO-20 across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check NP5 tangible net assets ratio to evaluate the tangible quality of the company's equity base.

Annual Cash Flow Quality Index for NEWRON PHARMACEUT. EO-20 (2024–2024)

Year-by-year earnings quality comparison for NEWRON PHARMACEUT. EO-20. For live market cap and the full company financial profile, see NEWRON PHARMACEUT. EO-20 (NP5) total market value.

Year Quality Index Operating CF (EUR) Net Income YoY Change
2024 -0.82x €-17.61 Million €21.39 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.